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Extranodal Interdigitating Dendritic Cell Sarcoma Presenting  
in the Pleura: A Case Report
Interdigitating dendritic cell sarcoma (IDCS) is an extremely rare neoplasm arising from the 
antigen-presenting cells of the immune system. This disease usually involves the lymph 
nodes, and rarely, extranodal sites may be affected. The authors report a case of extranodal 
IDCS presenting in the pleura. A 32-yr-old man presented with progressive chest pain. 
Imaging studies showed diffuse pleural thickening with pleural effusion. Morphological 
and immunohistochemical analysis of an incisional biopsy of the pleura were consistent 
with a diagnosis of IDCS; tumor cells were positive for S100 and CD45, but negative for 
CD1a, CD21, CD35, B cell and T cell markers. The patient was administered chemotherapy, 
but died of progressive disease. Although its incidence is extremely rare, this case suggests 
that extranodal IDCS should be considered in the differential diagnosis of undifferentiated 
neoplasms and that immunohistochemical staining be performed using appropriate 
markers.
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CASE REPORT
Oncology & Hematology
INTRODUCTION
Dendritic cells participate in the immune system as antigen-
presenting cells. Four different types of dendritic cells exist in 
lymph nodes, namely, histiocytic, fibroblastic, interdigitating, 
and follicular cells. Their main function is the presentation of 
antigens and the generation and regulation of the germinal cen-
ter reaction. Follicular dendritic cells participate in the immune 
system by presenting antigens for B cells and by stimulating B 
cell proliferation and differentiation. These cells are localized to 
areas of B cells in the germinal centers of lymphoid follicles. In-
terdigitating dendritic cells participate in the immune system 
by stimulating T lymphocytes and are found in the T cell areas 
of peripheral lymphoid tissues (1-3).  
  Dendritic cell neoplasms are rare tumors, though they are 
being recognized with increasing frequency. They were previ-
ously classified as lymphomas, sarcomas, or histiocytic neo-
plasms. However, the World Health Organization (WHO) clas-
sified dendritic cell neoplasms into five groups: Langerhans 
cell histiocytosis (LCH), Langerhans cell sarcoma (LCS), inter-
digitating dendritic cell sarcoma/tumor (IDCS), follicular den-
dritic cell sarcoma/tumor (FDCS), and dendritic cell sarcoma, 
not specified otherwise (4). IDCS are infrequent neoplasms, 
and therefore, a limited number of cases have been reported. 
Although most arise in lymph nodes, rare cases of IDCS have 
been described in extranodal sites, such as the spleen, small in-
testine, nasopharynx, skin, testis, ovary, urinary bladder, and 
tonsils (5-12).
  Here, we report a case of extranodal IDCS presenting in the 
pleura, a hitherto unreported site.
CASE DESCRIPTION
On October 1st, 2009, a 32-yr-old man visited the outpatient 
clinic with a 1-month history of progressively worsening blood- 
tinged sputum and chest pain. He had no relevant previous med-
ical history. The patient had worked in a small educational in-
stitute for three years, and was currently working as a company 
employee. However, he denied exposure to asbestos. On physi-
cal examination, hepatosplenomegaly and peripheral lymph-
adenopathy were absent, but a chest examination revealed re-
traction and tenderness of the left chest wall. Laboratory testing 
revealed hemoglobin 12.3 mg/dL, white cell count 11,100/μL, 
and platelet count 519 × 10
3/μL. Blood chemistry findings re-
vealed an alanine aminotransferase 42 IU/L, aspartate amino-
transferase 94 IU/L, and lactate dehydrogenase 451 IU/L. Com-
puted tomography (CT) of the chest showed irregular pleural 
thickening and pleural effusion in the left lung (Fig. 1). An inci-
sional biopsy of pleura was performed, and histologic findings 
suggested a malignant undifferentiated tumor. Microscopically, Han H-S, et al.  •  Extranodal Interdigitating Dendritic Cell Sarcoma Presenting in the Pleura
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the tumor showed an infiltrative growth pattern with a desmo-
plastic stroma. The tumor cells had oval to spindled nuclei, and 
indented nuclei were frequently observed. The chromatin was 
often vesicular with inconspicuous nucleoli. The cytoplasm of 
the tumor cells was abundant and slightly eosinophilic with an 
indistinct border (Fig. 2). In addition, immunohistochemistry 
was performed on the Benchmark automated immunostaining 
system (Ventana Medical System, Tuscon, AZ, USA). The mono-
clonal antibodies used were the following: S100 (1:800; Dako, 
Glostrup, Demark), vimentin (1:200; Dako), CD45 (1:100; Leica, 
Newcastle-upon-Tyne, UK), CK (1:600; Leica), myeloperoxidase 
(1:200; Leica), HMB45 (1:150; Leica), CD1a (1:20; Leica), CD20 
(1:200; Leica), CD21 (1:60; Leica), CD23 (1:100; Leica), CD31 (1: 
300; Leica), CD34 (1:20; Leica), CD56 (1:150; Leica), CK5 (1:300; 
Leica), WT-1 (1:40; Leica), calretrenin (1:100; Leica), CD68 (1:600; 
DiNonA, Iksan, Korea), CD3 (1:300; Neo, Fremont, USA), CD35 
(1:50; Cell marque, Rocklin, CA, USA), and CK6 (1:50; Thermo, 
Fremont, CA, USA). Immunohistochemistry showed that the 
tumor cells were positive for S100, CD45 (Fig. 3), vimentin, and 
CD68, but negative for cytokeratin (epithelial cell marker), my-
eloperoxidase (myeloid cell marker), HMB45 (melanoma mark-
er), CD1a (LCS marker), CD3 (T-cell marker), CD20 (B-cell mark-
Fig. 1. Computed tomography of the chest showed irregular pleural thickening and 
pleural effusion in the left lung.
Fig. 2. Pathologic features of an incisional biopsy of the pleura. (A) The growth pattern of the tumor is infiltrative with a desmoplastic stroma (H&E, × 100). (B) The tumor cells 
shows oval to spindled and indented nuclei and abundant cytoplasm with indistinct border (H&E, × 400).
A B
Fig. 3. Immunohistochemistry showed that the tumor cells were positive for (A) S100 and (B) CD 45 (× 400).
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er), CD21, CD23, CD35 (FDCS marker), CD31 (vascular endo-
thelial cell marker), CD34 (myeloid stem cell marker), CD56 
(neuroendocrine cell marker), CK5, CK6, WT-1, and calretrenin 
(mesothelioma marker). The proliferation index (Ki 67) of the 
neoplastic cells was approximately 25%. A diagnosis of IDCS was 
made based on histological and immunohistochemical findings. 
The patient underwent a positron emission tomography (PET)-
CT scan, which revealed 18-fluoro-deoxyglucose (FDG) uptake 
in the thickened pleura and whole axial skeleton (standardized 
uptake value (SUV); 10.5 and 9.8) compatible with malignant 
tissue (Fig. 4). Subsequently, the patient was treated with two 
courses of CHOP (cyclophosphamide, doxorubicin, vincristine, 
prednisone) and one course of IMEP (ifosfamide, methotrexate, 
etoposide, prednisolone). However, the pleura-based masses 
were aggravated, and he died of progressive disease 3 months 
after diagnosis.
 
DISCUSSION
Tumors arising from dendritic cells, such as, FDCS and IDCS, 
are very rare. Fewer than two hundreds of cases have been re-
ported to date (4), and only 37 cases of IDCS have been report-
ed in the English literature (5). IDCS usually is encountered in a 
lymph node, but extranodal IDCS is rare and can occur in a wide 
variety of sites (5-12). The recognition of extranodal IDCS re-
quires a high index of suspicion because of its rarity. We present 
a case of extranodal IDCS in the pleura that was diagnosed us-
ing a combination of morphologic and immunophenotypic char-
Fig. 4. Corresponding positron emission tomography (PET)-CT image showed 18- 
fluoro-deoxyglucose (FDG) uptake (standardized uptake value, SUV, 10.5 and 9.8), by 
thickened pleura of the left hemithorax and the whole axial skeleton, which was com-
patible with malignant tissue.
acterizations. As far as we know, only one case of IDCS with pleu-
ral effusion has been reported, in which malignant pleural effu-
sion occurred during disease course in a IDCS patient present-
ed with multiple lymphadenopathies (13). Moreover, the report-
ed case might not be IDCS due to its expression of surface CD1a 
in the tumor cells. To the best of our knowledge, this is the first 
case report to describe extranodal IDCS initially presented with 
diffuse pleural involvement. 
  The diagnosis was confirmed histologically on slides stained 
with hematoxylin and eosin and a wide panel of antibodies, 
which included probes recognizing antigens specifically ex-
pressed by follicular and interdigitating dendritic cells (2, 3). 
Neoplastic cells were large, fusiform spindle cells with indis-
tinct cell borders, oval central nuclei, finely dispersed chroma-
tin, and small but prominent nucleoli, and often formed a stori-
form or whorled, fascicular growth pattern. IDCS should be dif-
ferentiated from FDCS, LCS, S100 positive histiocytic tumors, 
melanoma, and fibroblastic reticular cell tumors. Immunohis-
tochemistry demonstrated neoplastic cells positivity for all his-
tiocytic markers, including CD68, lysozyme, and macrophage 
transcription factor PU.1, and showed that the dendritic cell 
markers fascin and S100 were strongly expressed. However, they 
were negative for CD1a (LCS marker), CD21/23/35 (FDCS mark-
er), CD20 (B cell marker), CD3 (T cell marker), and CD34 (my-
eloid stem cell marker) (5-8). Neoplastic cells in our case were 
strongly positive for S100 and negative for T cell, B cell, epitheli-
al, and follicular dendritic cell markers.  
  Treatments administered have varied in accord with clinical 
context of the affected patients. In patients with localized dis-
ease, surgical resection has been the mainstay treatment. The 
roles of chemotherapy and radiotherapy have not been clearly 
defined. Several chemotherapeutic regimens have been tried 
including CHOP, ABVD (doxorubicin, bleomycin, vinblastine, 
dacarbazine), DHAP (dexamethasone, cisplatin, high-dose cy-
tarabine), EPOCH (etoposide, prednisone, vincristine, cyclo-
phosphamide, doxorubicin), ICE (ifosfamide, carboplatin, eto-
poside), and cisplatin/epirubicin with limited response (1, 3, 6). 
For the greater part, the agents used are combination chemo-
therapies designed for the treatment of lymphoma. Remission 
durations are usually short, and limited results for bone marrow 
transplantation are not encouraging (3). Our patient was treated 
using the CHOP and IMEP regimens, but eventually succumbed 
to disease progression. 
  This case highlights the diagnostic difficulties associated with 
rare tumors. Furthermore, its unusual location, extreme rarity, 
and the morphological similarities between IDCS and FDCS 
and with other poorly differentiated tumors can easily delay di-
agnosis. The possibility of IDCS with an unusual extranodal site 
should be considered when an undifferentiated neoplasm with 
a mixed population of lymphocytes is encountered. 
  We present a case of extranodal IDCS presenting with diffuse Han H-S, et al.  •  Extranodal Interdigitating Dendritic Cell Sarcoma Presenting in the Pleura
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pleural involvement. Awareness of this tumor, particularly in ex-
tranodal sites, and the use of immunohistochemical stains with 
appropriate markers are crucial for arriving at a correct diagnosis. 
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